Learn about early diabetes symptoms, diabetic diet information, diabetes care, type 1 diabetes, insulin resistance and type 2 diabetes. Read the latest medical research on diabetes.
Stem cell-based treatment controls blood sugar in people with Type 1 diabetes
An innovative stem cell-based treatment for Type 1 diabetes can meaningfully regulate blood glucose levels and reduce dependence on daily insulin injections, according to new clinical trial results. The therapy aims to replace the insulin-producing beta cells that people with Type 1 diabetes lack. Dubbed VC-02, the small medical implant contains millions of lab-grown pancreatic islet cells, including beta cells, that originate from a line of pluripotent stem cells.
Novel molecular mechanisms in the early development of diabetes mellitus
Researchers conducted a gene expression analysis at the single-cell level on pancreatic islets from prediabetic and diabetic mouse models. Analysis results revealed upregulation of Anxa10 expression in pancreatic beta cells during the early phases of diabetes, attributed to elevated blood glucose levels. This elevated Anxa10 expression was found to influence intracellular calcium homeostasis, leading to a reduction in insulin secretory capacity.
Hormones have the potential to treat liver fibrosis
Researchers have discovered previously unknown changes in a specific type of liver cells, potentially opening avenues for a new treatment for liver fibrosis, a potentially life-threatening condition. Currently, there are no drugs available to treat liver fibrosis.
NHS Diabetes Prevention Programme may have global impact
As ten percent of the world's adult population is predicted to have diabetes by 2030, a major new study finds that the NHS Diabetes Prevention Programme has a positive effect on reducing risk of developing diabetes.
Semaglutide reduced cardiovascular events by 20% in certain adults
Semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes, according to new research. Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management in adults with obesity or overweight and have at least one other health issue. In the trial, patients treated with semaglutide lost an average of 9.4% of their body weight and experienced improvements in other risk factors for cardiovascular disease. Results from the 'SELECT -- Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes' trial were presented today during a late-breaking science session at the American Heart Association's Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine.